Optimind Pharma（OMND）株式概要Optimind Pharma Corp.はカナダでサイケデリック療法を提供している。 詳細OMND ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性2/6配当金0/6報酬当社が推定した公正価値より92%で取引されている 過去5年間の収益は年間45.5%増加しました。 リスク分析意味のある時価総額がありません ( CA$516K )株式の流動性は非常に低い マイナスの株主資本 収益が 100 万ドル未満 ( CA$124K )すべてのリスクチェックを見るOMND Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.005194.1% 割高 内在価値ディスカウントEst. Revenue$PastFuture-3m171k2016201920222025202620282031Revenue CA$124.0kEarnings CA$8.8kAdvancedSet Fair ValueView all narrativesOptimind Pharma Corp. 競合他社Global Health ClinicsSymbol: CNSX:MJRXMarket cap: CA$563.5kNewtopiaSymbol: TSXV:NEWUMarket cap: CA$866.3kJack Nathan MedicalSymbol: TSXV:JNHMarket cap: CA$871.0kJustera HealthSymbol: CNSX:VTALMarket cap: CA$1.2m価格と性能株価の高値、安値、推移の概要Optimind Pharma過去の株価現在の株価CA$0.00552週高値CA$0.0152週安値CA$0.005ベータ0.161ヶ月の変化0%3ヶ月変化n/a1年変化0%3年間の変化-83.33%5年間の変化n/aIPOからの変化-96.67%最新ニュースお知らせ • Sep 09Optimind Pharma Corp. announced that it expects to receive CAD 1.2 million in fundingOptimind Pharma Corp announced a private placement to issue 12,000,000 subscription receipts at an issue price of CAD 0.10 for the proceeds of CAD 1,200,000 on September 8, 2025. Finder's fees may be paid.Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).New Risk • Jul 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$310k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$310k free cash flow). Shares are highly illiquid. Negative equity (-CA$69k). Revenue is less than US$1m (CA$138k revenue, or US$100k). Market cap is less than US$10m (CA$515.7k market cap, or US$372.5k).Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).最新情報をもっと見るRecent updatesお知らせ • Sep 09Optimind Pharma Corp. announced that it expects to receive CAD 1.2 million in fundingOptimind Pharma Corp announced a private placement to issue 12,000,000 subscription receipts at an issue price of CAD 0.10 for the proceeds of CAD 1,200,000 on September 8, 2025. Finder's fees may be paid.Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).New Risk • Jul 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$310k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$310k free cash flow). Shares are highly illiquid. Negative equity (-CA$69k). Revenue is less than US$1m (CA$138k revenue, or US$100k). Market cap is less than US$10m (CA$515.7k market cap, or US$372.5k).Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).Reported Earnings • Aug 01First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024)First quarter 2025 results: CA$0.001 loss per share (improved from CA$0.004 loss in 1Q 2024). Revenue: CA$16.0k (down 61% from 1Q 2024). Net loss: CA$97.5k (loss narrowed 76% from 1Q 2024).お知らせ • Jul 05Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in fundingOptimind Pharma Corp. announced a private placement to issue 10,000,000 common shares at a price of CAD 0.05 per share for gross proceeds of up to CAD 500,000 on July 3, 2024. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.Reported Earnings • Jul 01Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023)Full year 2024 results: CA$0.014 loss per share (improved from CA$0.038 loss in FY 2023). Revenue: CA$123.0k (down 28% from FY 2023). Net loss: CA$1.40m (loss narrowed 55% from FY 2023).Board Change • Jan 26Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jan 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Jan 11Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.01 loss in 3Q 2023). Revenue: CA$26.7k (down 38% from 3Q 2023). Net loss: CA$104.4k (loss narrowed 89% from 3Q 2023).お知らせ • Jan 10Optimind Pharma Corp. Announces Executive ChangesOptimind Pharma Corp. announced that David Goodman, a member of the Company's Board of Directors, assumes the mantle of Chief Executive Officer ("CEO") with a forward-looking vision for Optimind's continued growth and innovation. Former CEO and Director, Tom Sipos, has gracefully stepped down due to personal reasons. The Company expresses gratitude to Mr. Sipos for his valuable contributions and extends best wishes for his future endeavors.Reported Earnings • Nov 01Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.01 loss in 2Q 2023)Second quarter 2024 results: CA$0.002 loss per share (improved from CA$0.01 loss in 2Q 2023). Revenue: CA$27.4k (down 36% from 2Q 2023). Net loss: CA$183.5k (loss narrowed 81% from 2Q 2023).Reported Earnings • Jul 30First quarter 2024 earnings releasedFirst quarter 2024 results: CA$0.004 loss per share. Net loss: CA$403.7k (flat on 1Q 2023).お知らせ • May 19Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023.お知らせ • Sep 21Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million.Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million on September 20, 2022. The acquisition was completed pursuant to an asset purchase agreement (the "APA") with Beatrice Society. Pursuant to the APA, the Company has issued a total of 22,500,000 common shares to the vendor which are subject to the following release terms: (i) 11,500,000 common shares are subject to a time release escrow as follows: (A) 5,343,750 are released on January 17, 2023; (B) 1,968,750 are released on March 17, 2023; (C) 1,968,750 are released on June 17, 2023; and, (D) (B) 1,968,750 are released on September 17, 2023; and (ii) 11,500,000 common shares are subject to earn-out milestones as follows: (A) 2,812,500 common shares; (B) 5,625,000 common shares; and (C) 2,812,500 common shares, with each of three earn-out milestones related to continued development of the protocols and courses for the acquired assets and intellectual property. Optimind Pharma Corp. (CNSX:OMND) completed the acquisition of MindSetting Inc. from Beatrice Society Inc. on September 20, 2022.株主還元OMNDCA HealthcareCA 市場7D0%1.0%1.0%1Y0%30.2%34.0%株主還元を見る業界別リターン: OMND過去 1 年間で30.2 % の収益を上げたCanadian Healthcare業界を下回りました。リターン対市場: OMNDは、過去 1 年間で34 % のリターンを上げたCanadian市場を下回りました。価格変動Is OMND's price volatile compared to industry and market?OMND volatilityOMND Average Weekly Movementn/aHealthcare Industry Average Movement5.7%Market Average Movement10.3%10% most volatile stocks in CA Market17.8%10% least volatile stocks in CA Market4.0%安定した株価: OMNDの株価は、 Canadian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のOMNDのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aDavid Goodmanoptimindpharma.comOptimind Pharma Corp.はカナダでサイケデリック療法を提供している。同社は、心的外傷後ストレス症候群、不安、うつ病、その他の精神疾患や障害の治療のために、ケタミン補助療法やその他のサイケデリック強化精神療法を提供するサイケデリック類似療法を提供している。また、クリニックを通じて医療用大麻やその他の代替療法も提供している。本社はカナダのトロント。もっと見るOptimind Pharma Corp. 基礎のまとめOptimind Pharma の収益と売上を時価総額と比較するとどうか。OMND 基礎統計学時価総額CA$515.74k収益（TTM）-CA$46.88k売上高(TTM)CA$124.01k4.2xP/Sレシオ-11.0xPER（株価収益率OMND は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計OMND 損益計算書（TTM）収益CA$124.01k売上原価CA$46.23k売上総利益CA$77.78kその他の費用CA$124.66k収益-CA$46.88k直近の収益報告Aug 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.00045グロス・マージン62.72%純利益率-37.80%有利子負債／自己資本比率-150.5%OMND の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/09 12:22終値2025/09/11 00:00収益2025/08/31年間収益2025/02/28データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Optimind Pharma Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Sep 09Optimind Pharma Corp. announced that it expects to receive CAD 1.2 million in fundingOptimind Pharma Corp announced a private placement to issue 12,000,000 subscription receipts at an issue price of CAD 0.10 for the proceeds of CAD 1,200,000 on September 8, 2025. Finder's fees may be paid.
Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).
New Risk • Jul 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$310k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$310k free cash flow). Shares are highly illiquid. Negative equity (-CA$69k). Revenue is less than US$1m (CA$138k revenue, or US$100k). Market cap is less than US$10m (CA$515.7k market cap, or US$372.5k).
Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).
Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).
Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).
お知らせ • Sep 09Optimind Pharma Corp. announced that it expects to receive CAD 1.2 million in fundingOptimind Pharma Corp announced a private placement to issue 12,000,000 subscription receipts at an issue price of CAD 0.10 for the proceeds of CAD 1,200,000 on September 8, 2025. Finder's fees may be paid.
Reported Earnings • Jul 31First quarter 2026 earnings released: EPS: CA$0 (vs CA$0.001 loss in 1Q 2025)First quarter 2026 results: EPS: CA$0 (improved from CA$0.001 loss in 1Q 2025). Revenue: CA$35.7k (up 123% from 1Q 2025). Net loss: CA$294 (loss narrowed 100% from 1Q 2025).
New Risk • Jul 31New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$310k This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$310k free cash flow). Shares are highly illiquid. Negative equity (-CA$69k). Revenue is less than US$1m (CA$138k revenue, or US$100k). Market cap is less than US$10m (CA$515.7k market cap, or US$372.5k).
Reported Earnings • Jun 30Full year 2025 earnings released: CA$0.002 loss per share (vs CA$0.014 loss in FY 2024)Full year 2025 results: CA$0.002 loss per share (improved from CA$0.014 loss in FY 2024). Revenue: CA$118.4k (down 3.7% from FY 2024). Net loss: CA$215.8k (loss narrowed 85% from FY 2024).
Reported Earnings • Jan 31Third quarter 2025 earnings released: EPS: CA$0 (vs CA$0.001 loss in 3Q 2024)Third quarter 2025 results: EPS: CA$0 (improved from CA$0.001 loss in 3Q 2024). Revenue: CA$26.6k (flat on 3Q 2024). Net loss: CA$9.0k (loss narrowed 91% from 3Q 2024).
Reported Earnings • Nov 01Second quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.002 loss in 2Q 2024)Second quarter 2025 results: CA$0.001 loss per share (improved from CA$0.002 loss in 2Q 2024). Revenue: CA$41.1k (up 50% from 2Q 2024). Net loss: CA$82.6k (loss narrowed 55% from 2Q 2024).
Reported Earnings • Aug 01First quarter 2025 earnings released: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2024)First quarter 2025 results: CA$0.001 loss per share (improved from CA$0.004 loss in 1Q 2024). Revenue: CA$16.0k (down 61% from 1Q 2024). Net loss: CA$97.5k (loss narrowed 76% from 1Q 2024).
お知らせ • Jul 05Optimind Pharma Corp. announced that it expects to receive CAD 0.5 million in fundingOptimind Pharma Corp. announced a private placement to issue 10,000,000 common shares at a price of CAD 0.05 per share for gross proceeds of up to CAD 500,000 on July 3, 2024. All securities issued in connection with the private placement will be subject to a statutory hold period expiring four months and one day from the date of issuance of the securities.
Reported Earnings • Jul 01Full year 2024 earnings released: CA$0.014 loss per share (vs CA$0.038 loss in FY 2023)Full year 2024 results: CA$0.014 loss per share (improved from CA$0.038 loss in FY 2023). Revenue: CA$123.0k (down 28% from FY 2023). Net loss: CA$1.40m (loss narrowed 55% from FY 2023).
Board Change • Jan 26Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jan 12Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Tushar Arora was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jan 11Third quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.01 loss in 3Q 2023)Third quarter 2024 results: CA$0.001 loss per share (improved from CA$0.01 loss in 3Q 2023). Revenue: CA$26.7k (down 38% from 3Q 2023). Net loss: CA$104.4k (loss narrowed 89% from 3Q 2023).
お知らせ • Jan 10Optimind Pharma Corp. Announces Executive ChangesOptimind Pharma Corp. announced that David Goodman, a member of the Company's Board of Directors, assumes the mantle of Chief Executive Officer ("CEO") with a forward-looking vision for Optimind's continued growth and innovation. Former CEO and Director, Tom Sipos, has gracefully stepped down due to personal reasons. The Company expresses gratitude to Mr. Sipos for his valuable contributions and extends best wishes for his future endeavors.
Reported Earnings • Nov 01Second quarter 2024 earnings released: CA$0.002 loss per share (vs CA$0.01 loss in 2Q 2023)Second quarter 2024 results: CA$0.002 loss per share (improved from CA$0.01 loss in 2Q 2023). Revenue: CA$27.4k (down 36% from 2Q 2023). Net loss: CA$183.5k (loss narrowed 81% from 2Q 2023).
Reported Earnings • Jul 30First quarter 2024 earnings releasedFirst quarter 2024 results: CA$0.004 loss per share. Net loss: CA$403.7k (flat on 1Q 2023).
お知らせ • May 19Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023Optimind Pharma Corp., Annual General Meeting, Jul 20, 2023.
お知らせ • Sep 21Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million.Optimind Pharma Corp. (CNSX:OMND) acquired MindSetting Inc. from Beatrice Society Inc. for CAD 1.6 million on September 20, 2022. The acquisition was completed pursuant to an asset purchase agreement (the "APA") with Beatrice Society. Pursuant to the APA, the Company has issued a total of 22,500,000 common shares to the vendor which are subject to the following release terms: (i) 11,500,000 common shares are subject to a time release escrow as follows: (A) 5,343,750 are released on January 17, 2023; (B) 1,968,750 are released on March 17, 2023; (C) 1,968,750 are released on June 17, 2023; and, (D) (B) 1,968,750 are released on September 17, 2023; and (ii) 11,500,000 common shares are subject to earn-out milestones as follows: (A) 2,812,500 common shares; (B) 5,625,000 common shares; and (C) 2,812,500 common shares, with each of three earn-out milestones related to continued development of the protocols and courses for the acquired assets and intellectual property. Optimind Pharma Corp. (CNSX:OMND) completed the acquisition of MindSetting Inc. from Beatrice Society Inc. on September 20, 2022.
